In 2024, the U.S. Drug Enforcement Administration (DEA) indicated which they intend to reclassify cannabis being a Schedule III drug. This rescheduling will acknowledge that cannabis has legitimate medical purposes and can help open up the doorway to study on other potential remedy uses. , as